Advancing patient healing and outcomes through novel supercritical CO2 solutions
NovaSterilis was launched in 2001 to commercialize a broad range of emerging combination (i.e. biologic/polymeric) products that were being introduced to the medical device market. These new products required gentle, low temperature, non-reactive sterilants with the ability to penetrate through packaging and product. scCO2, with its unique physical and chemical properties, proved to be an ideal target platform.
By 2006, NovaSterilis had developed an effective, safe and commercially viable terminal sterilization process using scCO2. The Company patented its novel sterilization process (the Nova Process™) and began commercial operations in 2007 selling the Nova2200™ sterilizer and a sterilization additive, NovaKill™.
NovaSterilis initial market focus was the human tissue banking industry. By 2015 regulatory agencies in the U.S.A. and Australia had approved products that utilized the Nova Process™ as the terminal sterilization modality. Over that time, allograft tissue sterilized with the Nova Process has been delivered and used worldwide in tens of thousands of surgeries.
NovaSterilis continues to serve the tissue banking and regenerative medicine markets with its equipment, additives and processes. Over the past few years, in addition to selling its equipment and additives, NovaSterilis has worked with numerous customers around the globe performing contract research on applications of scCO2 across a broad range of materials including biologic, polymeric, small molecule, large molecule, food, and agricultural.
In Q4 2017, the Company completed a renovation of its facilities and expanded its team in order to continue to meet the evolving needs of its customers.